References
- Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ. Update in the epidemiology risk factors screening and treatment of diabetic retinopathy. J Diabetes Investig. 2021;12(8):1322-5. DOI: 10.1111/jdi.13480
- Pandit S, Ho AC, Yonekawa Y. Recent advances in the management of proliferative diabetic retinopathy. Curr Opin Ophthalmol. 2023;34(3):232-6. DOI: 10.1097/ICU.0000000000000946
- Obasanmi G, Lois N, Armstrong D, Hombrebueno JMR, Lynch A, Chen M, et al. Peripheral blood mononuclear cells from patients with type 1 diabetes and diabetic retinopathy produce higher levels of il-17a il-10 and il-6 and lower levels of ifn-γ-a pilot study. Cells. 2023;12(3):467. DOI: 10.3390/cells12030467
- Bilgin B, Bilak S, Özay Y. Comparison of HIF-1α and survivin levels in patients with diabetes and retinopathy of varying severity. Arq Bras Oftalmol. 2024;87(4):e2023. DOI: 10.5935/0004-2749.2023-0112
- Andrés-Blasco I, Gallego-Martínez A, Machado X, Cruz-Espinosa J, Di Lauro S, Casaroli-Marano R, et al. Oxidative stress inflammatory angiogenic and apoptotic molecules in proliferative diabetic retinopathy and diabetic macular edema patients. Int J Mol Sci. 2023;24(9):8227. DOI: 10.3390/ijms24098227
- Goldney J, Sargeant JA, Davies MJ. Incretins and microvascular complications of diabetes:neuropathy nephropathy retinopathy and microangiopathy. Diabetologia. 2023;66(10):1832-45. DOI: 10.1007/s00125-023-05988-3
- Liu X, Zhou X, Song W, Zeng J, Niu X, Meng R. The diagnostic value of circulating vegf in diabetic retinopathy in asia: a systematic review and meta-analysis. Ophthalmic Epidemiol. 2023;30(3):230-8. DOI: 10.1080/09286586.2022.2088805
- Chaudhary V, Sarohia GS, Phillips MR, Park D, Xie J, Zeraatkar D, et al. Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema:a meta-analysis of trials. Eye. 2023;37(10):1966-74. DOI: 10.1038/s41433-022-02269-y
- Grauslund J, Andersen N, Andresen J, Flesner P, Haamann P, Heegaard S, et al. Evidence-based Danish guidelines for screening of diabetic retinopathy. Acta Ophthalmol. 2018;96(8):763-9. DOI: 10.1111/aos.13936
- Venkatesh R, Reddy N, Jayadev C, Pulipaka RS, Yadav NK, Basavaraj TM. Proliferative diabetic retinopathy detection:Comparison of clinical examination, optomap photographs and fluorescein angiography. Nepal J Ophthalmol. 2022;14(28):86-96. DOI: 10.3126/nepjoph.v14i2.39516
- Guo C, Deshpande M, Niu Y, Kachwala I, Flores-Bellver M, Megarity H, et al. HIF-1α accumulation in response to transient hypoglycemia may worsen diabetic eye disease. Cell Rep. 2023;42:111976. DOI: 10.1016/j.celrep.2022.111976
- Garber D, Zhu S. Implications of Caspase 1/Interleukin-1 Beta (IL-1β) Signaling and Hypoxia-Inducible Factor 1-Alpha (HIF-1α) on Diabetic Retinopathy Pathology. Cureus. 2023;15(7):e42479. DOI: 10.7759/cureus.42479
- Xu Y, Zou H, Ding Q, Zou Y, Tang C, Lu Y, et al. tiRNA-Val promotes angiogenesis via Sirt1-Hif-1α axis in mice with diabetic retinopathy. Biol Res. 2022;55(1):14. DOI: 10.1186/s40659-022-00381-7
- Chen B, Zou J, Xie L, Cai Y, Li B, Tan W, et al. WNT-inhibitory factor 1-mediated glycolysis protects photoreceptor cells in diabetic retinopathy. J Transl Med. 2024;22(1):245. DOI: 10.1186/s12967-024-05046-5
- Liu C, Cheng T, Wang Y, Li G, Wang Y, Tian W, et al. Syringaresinol Alleviates Early Diabetic Retinopathy by Downregulating HIF-1α/VEGF via Activating Nrf2 Antioxidant Pathway. Mol Nutr Food Res. 2024;68(4):e2200771. DOI: 10.1002/mnfr.202200771
- Li HY, Yuan Y, Fu YH, Wang Y, Gao XY. Hypoxia-inducible factor-1α:A promising therapeutic target for vasculopathy in diabetic retinopathy. Pharmacol Res. 2020;159:104-7. DOI: 10.1016/j. phrs.2020.104924
- Shakthiya T, Chand L, Annamalai R, Ka AS. Exploring the Association of VEGF-A and ANGPTL2 with the Prognosis of Nonproliferative and Proliferative Diabetic Retinopathy. Cureus. 2024;16(8):e68273. DOI: 10.7759/cureus.68273
- Fickweiler W, Park H, Park K, Mitzner MG, Chokshi T, Boumenna T, et al. Elevated Retinol Binding Protein 3 Concentrations Are Associated With Decreased Vitreous Inflammatory Cytokines VEGF and Progression of Diabetic Retinopathy. Diabetes Care. 2022;45(9):2159-62. DOI: 10.2337/dc22-0165
- Loporchio DF, Tam EK, Cho J, Chung J, Jun GR, Xia W, et al. Cytokine Levels in Human Vitreous in Proliferative Diabetic Retinopathy. Cells. 2021;10(5):1069. DOI: 10.3390/cells10051069
- Chen-Li G, Martinez-Archer R, Coghi A, Roca JA, Rodriguez FJ, Acaba-Berrocal L, et al. Beyond VEGF:Angiopoietin-Tie Signaling Pathway in Diabetic Retinopathy. J Clin Med. 2024;13(10):2778. DOI: 10.3390/jcm13102778
- Rezzola S, Guerra J, Krishna Chandran AM, Loda A, Cancarini A, Sacristani P, et al. VEGF-Independent Activation of Müller Cells by the Vitreous from Proliferative Diabetic Retinopathy Patients. Int J Mol Sci. 2021;22(4):2179. DOI: 10.3390/ijms22042179
- Keles A, Sonmez K, Erol YO, Ayyıldız SN, Ogus E. Vitreous levels of vascular endothelial growth factor, stromal cell-derived factor-1α, and angiopoietin-like protein 2 in patients with active proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2021;259(1):53-60. DOI: 10.1007/s00417-020-04889-0
- Ecsedy M, Kovacs I, Szigeti A, Horvath H, Lenart L, Recsan Z, et al. Association of SDF-1-3’ Gene A Variant with Diabetic Retinopathy in the Hungarian Population. Int J Mol Sci. 2024;25(15):8036. DOI: 10.3390/ijms25158036
- Monickaraj F, Oruganti SR, McGuire P, Das A. A potential novel therapeutic target in diabetic retinopathy:a chemokine receptor (CCR2/CCR5) inhibitor reduces retinal vascular leakage in an animal model. Graefes Arch Clin Exp Ophthalmol. 2021;259(1):93-100. DOI: 10.1007/s00417-020-04884-5